# Pembrolizumab and Radiation Therapy in Patients With Relapsed or Refractory Multiple Myeloma

> **NCT03267888** · PHASE1,PHASE2 · COMPLETED · sponsor: **Emory University** · enrollment: 25 (actual)

## Conditions studied

- ISS Stage I Plasma Cell Myeloma
- ISS Stage II Plasma Cell Myeloma
- ISS Stage III Plasma Cell Myeloma
- Recurrent Plasma Cell Myeloma
- Refractory Plasma Cell Myeloma

## Interventions

- **BIOLOGICAL:** Pembrolizumab
- **RADIATION:** Radiation Therapy

## Key facts

- **NCT ID:** NCT03267888
- **Lead sponsor:** Emory University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-05-29
- **Primary completion:** 2022-09-02
- **Final completion:** 2022-09-02
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2024-09-04

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03267888

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03267888, "Pembrolizumab and Radiation Therapy in Patients With Relapsed or Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03267888. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*